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Kalucka et al. show that fatty acid
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QECs reprogram their metabolism to
increase regeneration of NAPDH, which is
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Little is known about the metabolism of quiescent
endothelial cells (QECs). Nonetheless, when dys-
functional, QECs contribute to multiple diseases.
Previously, we demonstrated that proliferating endo-
thelial cells (PECs) use fatty acid b-oxidation (FAO)
for de novo dNTP synthesis. We report now that
QECs are not hypometabolic, but upregulate FAO
>3-fold higher than PECs, not to support biomass
or energy production but to sustain the tricarboxylic
acid cycle for redox homeostasis through NADPH
regeneration. Hence, endothelial loss of FAO-con-
trolling CPT1A in CPT1ADEC mice promotes EC
dysfunction (leukocyte infiltration, barrier disruption)
by increasing endothelial oxidative stress, renderingCell MeCPT1ADEC mice more susceptible to LPS and inflam-
matory bowel disease. Mechanistically, Notch1 or-
chestrates the use of FAO for redox balance in
QECs. Supplementation of acetate (metabolized to
acetyl-coenzyme A) restores endothelial quiescence
and counters oxidative stress-mediated EC dysfunc-
tion in CPT1ADEC mice, offering therapeutic opportu-
nities. Thus, QECs use FAO for vasculoprotection
against oxidative stress-prone exposure.
INTRODUCTION
Dysfunctional endothelial cells (ECs) contribute to numerous
diseases with high morbidity and mortality, including atheroscle-
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worldwide. Hence, reversal or prevention of EC dysfunction is a
therapeutic objective, and understanding how quiescent endo-
thelial cells (QECs) protect themselves against dysfunction is an
unmet medical need. Most ECs in a healthy adult are quiescent
(Eelen et al., 2018). They mediate tissue perfusion, counteract
thrombosis and vascular inflammation, and maintain vasoregula-
tion and barrier function (Chistiakov et al., 2017; Incalza et al.,
2018). QECs are, however, exposed to high oxygen levels, and
thus prone to oxidative stress (Polet and Feron, 2013), known to
induce EC dysfunction inmultiple cardiovascular disorders (Chis-
tiakov et al., 2017). We hypothesized that QECs must therefore
possess metabolic mechanisms to protect themselves against
oxidative stress. However, a possible involvement of cellular
metabolism in EC quiescence has not been considered, and it is
unknown whether metabolic changes accompany or underlie
the vasculoprotective homeostatic phenotype of QECs.
Nonetheless, a role for ECmetabolism is suggested. Indeed, (1)
ECdysfunction can result fromenhanced oxidative stress, gener-
ated by uncoupled endothelial nitric oxide synthase (eNOS) and
mitochondrial respiration (Eelen et al., 2018). (2) Pathways
sensing changes in cellular energy balance are altered by oxida-
tive stress in dysfunctional ECs (Donato et al., 2015). (3) Dietary
glycine modulates glutathione biosynthesis, which protects ECs
against oxidative stress (Ruiz-Ramirez et al., 2014). (4) Reactive
oxygen species (ROS)-scavenging systems such as glutathione
peroxidase require reduced glutathione (GSH), which is regener-
ated from its oxidized form (GSSG) by NADPH-dependent gluta-
thione reductase (Gorrini et al., 2013). Aside from this fragmentary
evidence, it remains unknown if and how QECs reprogram their
metabolism to adopt a vasculoprotective phenotype.
When QECs become angiogenic, they increase glycolysis to
promote migration and proliferation (De Bock et al., 2013). In
proliferating ECs (PECs), fatty acid b-oxidation (FAO) is impor-
tant to sustain the tricarboxylic acid (TCA) cycle in conjunction
with an anaplerotic carbon source to support nucleotide synthe-
sis (Schoors et al., 2015), while ECs forming a vascular network
in a matrix also upregulate FAO (Patella et al., 2015). In contrast,
FOXO1, promoting growth arrest, decreases glycolysis in ECs
(Wilhelm et al., 2016). Hence, one might expect that QECs would
be hypometabolic, although this remains untested. Here, we
characterized how ECs reprogram their metabolism when
switching from proliferation to quiescence.
RESULTS
Transcriptomic Signature of Metabolic Genes in
Quiescent Endothelial Cells
To induce quiescence of ECs, we used two complementary
methods. We cultured human umbilical vein endothelial cellsFigure 1. Metabolic Transcriptomics of QECs versus PECs
(A) Percentage of EdUneg cells (left) and [3H]thymidine incorporation into DNA (
disintegrations per minute. Statistics: mixed models statistics. Data are mean ±
(B) Correlation heatmap and hierarchical cluster analysis of transcript levels of 1,4
biological replicates with 3 technical replicates each). Color scale: red, high corr
(C) Heatmap of transcript levels of FAO, oxPPP, non-oxPPP, and glycolytic genes
replicates each). Color scale: red, high correlation; blue, low correlation.
(D) Pathway map showing changes in transcript levels of genes in central carbon m
least 15%; gray: unchanged, change <15%; blue: downregulated by at least 15%
See also Figure S1 and Tables S1, S2, and S3.(referred to hereafter as ‘‘ECs’’) until they were contact inhibited
(Noseda et al., 2004), or stimulated ECs with Dll4 to activate pro-
quiescent Notch signaling (Harrington et al., 2008), yielding
similar results. With either approach, fewer ECs proliferated,
while more cells resided in the G0 phase (Figures 1A and S1A)
and elevated the expression of downstream Notch-target
genes (Figures S1B and S1C), without signs of senescence
(Figure S1D). We assessed global metabolic changes induced
by quiescence by performing an unbiased transcriptomics anal-
ysis in proliferating ECs (PECs) versus quiescent ECs (QECs),
focusing on the 1,444 detected metabolic genes. Correlation
heatmap analysis and hierarchical clustering revealed that
QECs and PECs grouped into distinct metabolic clusters
(p < 0.05), indicating different metabolic gene signatures
(Figure 1B).
QECs Upregulate Fatty Acid Oxidation
Cell quiescence has been associated with cellular hypometab-
olism (Wilhelm et al., 2016). Surprisingly, therefore, of the ten
self-contained gene sets of central carbon metabolism, rotation
gene set test (ROAST) analysis revealed that FAO was the only
significantly upregulated pathway and had the highest fraction
of upregulated genes of all pathways in central metabolism
(false discovery rate-adjusted p = 1.00 3 104). An opposite
effect or trend was observed for glycolysis, serine biosynthesis,
TCA cycle, oxidative phosphorylation (OXPHOS), and nucleo-
tide and fatty acid synthesis (Table S1). By heatmap and
pathway mapping analysis, QECs upregulated transcripts of
various FAO genes (some only modestly), while lowering
transcripts of genes involved in glycolysis, TCA cycle, purine/
pyrimidine synthesis, and pathways contributing to nucleotide
synthesis (non-oxidative pentose phosphate pathway, one-
carbon metabolism) (Figures 1C, 1D, and S1E; see Tables S2
and S3 for full name of genes), consistent with their lower
proliferation rate and anabolic need (Figure 1A). Since PECs
utilize FAO to support nucleotide synthesis (Schoors et al.,
2015), we had expected that QECs would have lower, not
higher FAO levels, since QECs synthesize fewer nucleotides
as they proliferate less. We therefore focused on the surprising
finding that FAO gene expression was higher in QECs than
in PECs.
Endothelial Cells Increase FAO Flux when Becoming
Quiescent
FAO flux increased when ECs became quiescent, up to 3- to
4-fold higher than in PECs (Figures 2A, 2B, and S2A), while
glycolytic flux and glucose consumption were reduced (Figures
2A, 2C, 2D, and S2B). Glucose and glutamine oxidation, and
fatty acid synthesis were also reduced in QECs (Figures 2E–2Gproliferation assay; right) in contact-inhibited QECs and PECs (n = 3). DPM,
SEM; *p < 0.05.
44 metabolic genes of central carbon metabolism in QECs versus PECs (n = 4
elation; blue, low correlation.
in contact-inhibited QECs and PECs (n = 4 biological replicates with 3 technical
etabolism in QECs relative to PECs. Color scale: red, upregulated genes by at
. For full gene names, see Tables S2 and S3.






Figure 2. Metabolic Adaptations upon Induction of EC Quiescence
(A) Progressive changes of EC metabolism (glycolysis, red; FAO, blue) and proliferation ([3H]thymidine incorporation, black) during induction of contact-inhibited
EC quiescence (n = 4).
(B–F) FAO (B), glycolytic rate (C), glucose consumption (D), glucose oxidation (E), and glutamine oxidation (F) in contact-inhibited QECs versus PECs (n = 3–8).
(G) Fatty acid synthesis measured by [U-14C]acetate incorporation in fatty acids, in QECs versus PECs (n = 4).
(H) Representative immunoblot (n = 5) for NICD, CPT1A, and PFKFB3 during induction of EC quiescence by contact inhibition. a-Tubulin was used as loading
control. For densitometric quantifications, see Table S4.
(I) qRT-PCR analysis of CPT1A in contact-inhibited QECs relative to PECs (n = 5).
In (A) and (H), proliferating ECs (day 1) are standard proliferating cultures. In (B) to (G) and (I), PECs were obtained by reseeding QECs, which initiates
cell proliferation. DPM, disintegrations per minute. Statistics: mixed models statistics (A–C and E–G), two-tailed t test with Welch correction (D and I). Data are
mean ± SEM; *p < 0.05 versus day 1 (A) or versus PEC (B–G and I). See also Figures S2 and S3; Tables S4 and S5.and S2C–S2E). Expression of CPT1A, a rate-controlling enzyme
of FAO (Schoors et al., 2015), was increased, while that of
PFKFB3, a glycolytic activator (De Bock et al., 2013), declined
when ECs became quiescent (Figures 2H, 2I, S2F, and S2G;
Table S4). Similar metabolic changes were detected in arterial
ECs (Figures S2H and S2I). Use of other models of EC quies-
cence, based on exposing ECs to physiological shear stress
(Lin et al., 2000), confirmed higher CPT1A expression (Figures
S2J and S2K).884 Cell Metabolism 28, 881–894, December 4, 2018FAO Is Dispensable for Energy Homeostasis, Biomass
Synthesis, and Histone Acetylation in QECs
As cells use FAO for ATP and acetyl-coenzyme A (CoA) produc-
tion (Ghesquiere et al., 2014; Xiong et al., 2018), redox homeo-
stasis (Harjes et al., 2016), epigenetic regulation (Wong et al.,
2017), or DNA synthesis (Schoors et al., 2015), we assessed
for which purpose QECs increased FAO, by comparing QECs
versus PECs, and by knockdown of CPT1A (CPT1AKD) using
two lentiviral vectors, each expressing a different short hairpin
A B C
ED
Figure 3. FAO-Derived Carbons Contribute to the TCA Cycle in QECs in Dll4-Induced QECs
(A) Total contribution of [13C]palmitate carbons to the indicated TCA intermediates in QECs versus PECs (n R 4).
(B and C) Analysis of m+4 (B) and m+3 (C) labeled TCA intermediates (from [U-13C]palmitate) in QECs versus PECs (n = 5).
(D) Total contribution of [13C]glutamine carbons to a-KG (n = 3).
(E) Calculation of relative pyruvate carboxylase (PC)-dependent anaplerosis in QECs versus PECs (n R 4). a-KG, a-ketoglutarate.
Statistics: mixed models statistics. Data are mean ± SEM; *p < 0.05.RNA (Schoors et al., 2015) and reducing CPT1A and FAO levels
(Figures S3A–S3C). This combined approach revealed that
CPT1A-driven FAO was dispensable for energy homeostasis
(Figures S3D–S3I), biomass synthesis (Figures S3J–S3R), and
histone acetylation (Figures S3S and S3T; Table S5), and that
these processes were not affected by CPT1AKD. We thus
explored whether QECs utilized FAO for redox homeostasis.
IncreasedContribution of Fatty Acid-DerivedCarbons to
the TCA Cycle in QECs
To analyze how QECs utilize fatty acids (FAs), we supplemented
[U-13C]palmitate and determined 13C-label incorporation into
TCA-cycle intermediates, revealing that the total contribution
of 13C carbons to TCA-cycle intermediates was higher in QECs
than in PECs (Figure 3A). Mass distribution analysis revealed
an increase in m+4 citrate andm+3 a-ketoglutarate (aKG), fuma-
rate, and malate in QECs, suggesting that FA-derived carbons
sustained an oxidative TCA cycle in QECs (Figures 3B, 3C, and
S3U). However, even though QECs used FA-derived carbons
to sustain the TCA-cycle flux to a larger extent than PECs, ana-
plerotic replenishment of the TCA cycle by glutamine and
glucose was reduced in QECs, consistent with their lower anab-
olism (Figures 3D and 3E).
QECs Increase FAO for NADPH Regeneration
In cancer cells, FAO regulates redox homeostasis by generating
acetyl-CoA to sustain the TCA cycle (Rohrig and Schulze, 2016;Smolkova and Jezek, 2012). Indeed, the TCA-cycle metabolites
(iso)citrate and malate serve as substrates for reactions medi-
ated by isocitrate dehydrogenase (IDH) and malic enzyme (ME)
to regenerate NADPH from NADP+ (Rohrig and Schulze, 2016;
Smolkova and Jezek, 2012). Transcript levels of mitochondrial
IDH2 andME3were higher in QECs (Figures 4A and 4B), and par-
tial knockdown of IDH2 and ME3 increased the NADP+/NADPH
ratio in QECs (Figures S4A and S4B; more complete knockdown
was toxic). NADPH levels were higher in QECs (Figure 4C), while
CPT1AKD lowered the elevated NADPH levels in QECs to levels
observed in PECs, and increased the NADP+/NADPH ratio
(Figures 4C and S4C). CPT1AKD did not affect NADPH regener-
ation in PECs (Figure 4C), consistent with findings that PECs
do not use FAO for redox homeostasis (Schoors et al., 2015).
QECs expressed higher transcript levels of genes involved in
NAD(P) production, including nicotinamide N-methyltransferase
(NNMT), nicotinate phosphoribosyltransferase (NAPRT), NAD
synthetase 1 (NADSYN1), and nicotinamide riboside kinase 1
(NMRK1) (Figure 4D). Thus, the elevated NADPH levels in
QECs result from a combined effect on increased NADP+ syn-
thesis and on regeneration of NADPH from NADP+ by the
increased use of FA-derived carbons to sustain the TCA cycle.
QECs Have Reduced Oxidative Stress
Since NADPH is used by glutathione reductase to convert
oxidized glutathione (GSSG) to its reduced form (GSH), a key






Figure 4. Role of FAO in Redox Homeostasis
(A and B) qRT-PCR analysis of IDH1, IDH2 (A), and ME1, ME2, ME3 (B) in QECs relative to PECs (n R 3).
(C) Total intracellular NADPH levels in ctrl and CPT1AKD QECs or PECs (n = 3).
(D) qRT-PCR analysis of NNMT, NAPRT1, NADSYN1, and NMRK1 in QECs relative to PECs (n R 3).
(E–H)Oxidizedglutathione levels (percent of totalGSSG+GSH, expressed relative toPECs) in PECsand contact inhibition-inducedQECs (E, n = 3), intracellularROS
levels (CM-H2DCFDA fluorescence) in PECs and QECs (F, n = 8), intracellular ROS levels (CM-H2DCFDA fluorescence) of ctrl or CPT1A
KD QECs (G, n = 5), and total
intracellular NADPH levels (H, n = 3) in PECs and contact inhibition-induced QECs, in baseline and upon supplementation with H2O2 (50 mM, 2 hr). Unless otherwise
indicated, all experiments were performed using the Dll4-induced quiescence model. AU, arbitrary units.
Statistics: two-tailed t test with Welch correction (A, B, and D), ANOVA and Bonferroni post hoc test (C, E, and H), mixed models statistics (F and G). Data are
mean ± SEM; ns, not significant; *p < 0.05. See also Figure S4.in baseline conditions and upon exposure to exogenous H2O2
(a measure of the cell’s capacity to cope with elevated oxidative
stress) (referred to as ‘‘stress conditions’’). Levels of GSSG
(percent of total GSSG + GSH) and cellular ROS were lower in
QECs in baseline and stress conditions (Figures 4E and 4F). In886 Cell Metabolism 28, 881–894, December 4, 2018line with this, CPT1AKD in QECs increased ROS and GSSG
levels, supporting a role of FAO in counteracting oxidative stress
(Figures 4G and S4D). Unlike PECs, QECs increased NADPH
regeneration while maintaining a lower NADP+/NADPH ratio in
baseline and stress conditions (Figures 4H and S4E). Silencing
A B C
D E
Figure 5. Effect of Notch Signaling on CPT1A Expression
(A) qRT-PCR analysis of CPT1A in QECs without or with treatment with DAPT (n = 3).
(B) FAO in QECs without or with treatment with DAPT (n = 8).
(C) ChIP-qPCR analysis of NICD binding to the CPT1A promoter at the NICD-RBPjk consensus interaction site (IS) 1, 2, or 3, in PECs or QECs, treated or not with
DAPT and pulled down with anti-Notch1 (aNotch1) or immunoglobulin G (IgG) antibody. Data are presented as percentage of input (n = 4).
(D) ChIP-qPCR analysis of NICD binding to theCPT1A promoter at the binding site (IS) 1, 2, or 3 in control ECs (pRRL) and in ECs overexpressing V5-taggedNICD
(NICDOE). Samples were pulled down with anti-V5 (aV5) or IgG antibody and the data are presented as percentage of input (n = 4).
(E) Relative luciferase activity of reporter constructs driven by a minimal promoter alone (ctrl) or together with NICD-RBPjk interaction site 1, 2, or 3 of the CPT1A
promoter, in control or NICDOE ECs (n = 3).
Unless otherwise indicated, all experiments were performed using the contact inhibition-induced quiescence model. Statistics: two-tailed t test with Welch
correction (A), mixed models statistics (B), ANOVA and Bonferroni post hoc test (C and D), two-tailed t test with Welch correction and one sample t test (E). Data
are mean ± SEM; *p < 0.05; ns, not significant. See also Figure S5.of ACADvl andHADHB (ACADvlKD/HADHBKD) (catalyzing critical
steps of FAO) similarly increased ROS levels (Figures S4F–S4H),
indicating that FAO, and not only CPT1A-mediated fatty acid
import in mitochondria, controls redox homeostasis in QECs.
As different species of ROS such as superoxide (O2
.),
hydrogen peroxide (H2O2), or hydroxyl radical (OH
) may have
different biological functions (Birben et al., 2012; Schieber and
Chandel, 2014), yet excess of each of them can trigger EC
dysfunction (Incalza et al., 2018), we characterized the ROS spe-
cies. Use of complementary assays revealed that mitochondrial/
cellular levels of O2
., H2O2, and OH were all reduced in QECs
(Figures S4I–S4O). Overall, QECs are better equipped to scav-
enge ROS and to cope with oxidative stress.
Molecular Mechanism of Upregulation of FAO in QECs
As QECs upregulated Notch signaling and Notch activation pro-
moted EC quiescence (see above), we focused on Notch as apossible transcriptional activator of CPT1A gene expression in
QECs. Blocking Notch signaling with DAPT (N-[N-(3,5-difluoro-
phenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) in QECs
decreased CPT1A expression and FAO flux (Figures 5A and
5B). We then investigated whether Notch signaling increased
CPT1A transcription. The transcriptionally active Notch intracel-
lular domain (NICD) does not bind to DNA directly, but only via
interaction with RBPJk, a DNA-binding protein (Castel et al.,
2013). Notably, we identified four putative RBPJk-binding motifs
(Castel et al., 2013) in close proximity to the start codon of the
CPT1A gene (referred to as interaction site 1 [IS1], IS2, IS3,
and IS4) (Figure S5A).
Chromatin immunoprecipitation (ChIP)-qPCR analysis, using
an anti-Notch1 (aNotch1) antibody that captures NICD, re-
vealed an interaction of NICD with three of the four identified
sites (IS1, IS2, and IS3) in QECs, which was reduced upon
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Figure 6. Role of FAO in EC Barrier Function and Vasculoprotection In Vivo and In Vitro
(A and B) qRT-PCR analysis of enzymes involved in glutathione metabolism (Prdx1, Glrx2, and Gpx3) (A) and enzymes of the pentose phosphate pathway (PPP)
(G6pdx) (B) in ECs freshly isolated from wild-type (WT) and EC-specific CPT1A knockout (CPT1ADEC) mice (n R 3).
(C and D) O2
. formation in the portal vein in WT and CPT1ADEC mice at 4 and 12 hr after injection of vehicle (PBS) or LPS, evaluated by staining for the oxidative
fluorescent dye dihydroethidium (DHE). (C) Representative photomicrographs of portal vein open book preparations from the 12-hr treatedmice, stained for DHE
(red), the EC marker isolectin B4A (green), and nuclei (Hoechst; blue). Lower panels show larger magnifications of the boxed areas in the upper panels.
(D) Quantification of DHE fluorescence signal normalized for Hoechst fluorescence, and expressed relative to control (n = 3 independent experiments, each
comprising n > 4 mice per group).
(E) qRT-PCR analysis of PAI-1 in QECs upon single or combined treatment with etomoxir and LPS (to induce oxidative stress) (n = 4).
(legend continued on next page)
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tested ECs overexpressing V5-tagged NICD (NICDOE), which,
as expected (given that Notch is a pro-quiescent signal), were
more quiescent, and had increased levels of FAO and CPT1A
transcripts (Figures S5D–S5G). Use of an anti-V5 tag antibody
(aV5) showed that NICD interacted with IS1, IS2, and IS3 in
NICDOE but not control ECs (Figures 5D, S5H, and S5I). Cloning
of the CPT1A fragments, containing the IS1, IS2, and IS3
sequences, in luciferase reporter constructs with a minimal pro-
moter confirmed that NICDOE enhanced the luciferase activity,
as a parameter of increased CPT1A gene transcription (Fig-
ure 5E). Thus, Notch signaling upregulates FAO flux, at least
in part via induction of CPT1A gene expression. Similar ana-
lyses showed that Notch regulated the expression of IDH2
and ME3, involved in NADPH regeneration and redox homeo-
stasis in QECs (Figures S5J and S5K).
FAO Inhibition due to Loss of CPT1A in QECs Causes
Oxidative Stress In Vivo
To translate our in vitro findings, we used two in vivo approaches:
(1) adult 8-week-old mice (containing only/primarily QECs) with a
conditional inactivation of CPT1A in ECs (Cdh5(PAC)-CreERT2-
CPT1Alox/lox mice) upon tamoxifen treatment (referred to as
‘‘CPT1ADEC mice’’) (Schoors et al., 2015) (Figures S6A and
S6B); and (2) young P8 mice (in which growing blood vessels
contain both PECs and QECs) treated with etomoxir, an irrevers-
ible pharmacological blocker of CPT1 that lowers FAO levels in
ECs (Schoors et al., 2015).
RNA sequencing or RT-PCR analysis showed that freshly iso-
lated CPT1ADEC QECs upregulated the expression of genes
involved in redox homeostasis, presumably to restore redox ho-
meostasis. Gene set enrichment analysis and pathway mapping
revealed that glutathione metabolism, a key pathway in redox
homeostasis, ranked among the top three most upregulated
pathways inQECsofCPT1ADECmice (p = 0.0017; padjusted = 0.03)
(Figure S6C and Table S6). RT-PCR confirmed the upregulation
of enzymes involved in ROS scavenging (e.g., peroxiredoxin-1
[Prdx1], mitochondrial glutaredoxin-2 [Glrx2], glutathione perox-
idase 3 [Gpx3]) (Figure 6A). Also, the rate-controlling enzyme of
the oxidative PPP (pentose phosphate pathway; glucose-6-
phosphate dehydrogenase [G6pdx]), generating NADPH in
the cytosol, was upregulated in CPT1ADEC QECs (Figure 6B),(F) Leukocyte adhesion to a QEC monolayer upon single or combined treatment
(G) Quantification of CD45+ cells in the lungs of WT and CPT1ADEC mice, 4 hr af
(H) TEER analysis of QEC monolayers upon single or combined treatment with e
(I) Representative images of QECs and PECs, stained for VE-cadherin (red), withou
junctions; yellow arrowheads denote continuous junctions; asterisk denotes a ga
(J) Quantification of discontinuous junctions in quiescent QECs versus PECs wit
(K) qRT-PCR analysis of PAI-1 in QECs upon treatment with etomoxir and LPS (t
(n = 3).
(L) TEER measurements over 8 consecutive days, without (black lines) or with
mitoTEMPO treatment (dashed lines) (n = 5). Arrows indicate initiation of treatme
(M) Disease activity index (DAI) of colitis in WT and CPT1ADEC mice during treatm
(N) Colon length of WT and CPT1ADEC mice after DSS treatment. The values are
(O) CD45+ cell infiltration in the colon wall in WT and CPT1ADEC mice after DSS t
(P) Quantification of vascular leakiness (histological analysis of extravascular dex
All in vitro experiments were performed using the contact inhibition-induced quies
to form a monolayer of contact-inhibited QECs, we treated contact-inhibited QE
tailed t test with Welch correction (A, B, D, G, K, and M–P), ANOVA and Bonfe
mean ± SEM; ns, not significant, *p < 0.05 and #p < 0.05. In (L) asterisks (*) deno
etomoxir and etomoxir plus mitoTEMPO. Scale bars, 50 mm (C, upper panels), 2in line with an increased oxPPP flux in QECs upon CPT1AKD
(Figure S6D). Thus, CPT1ADEC QECs upregulate metabolic
pathways producing NADPH, presumably to restore redox
homeostasis.
We then assessed whether CPT1ADEC QECs elevated ROS
levels in intact vessels by staining for the ROS marker dihydroe-
thidium (DHE) and the EC marker isolectin using the aorta and
portal vein open book preparation (Sumiyoshi et al., 2008).
DHE levels were comparable in ECs in wild-type (WT) and
CPT1ADEC mice in baseline conditions (Figures 6C, 6D, S6E,
and S6F). However, upon administration of lipopolysaccharide
(LPS), which induces EC dysfunction, vascular damage, and
leakage because of ROS production (Kratzer et al., 2012), intra-
cellular ROS levels in QECs were higher in CPT1ADEC mice (Fig-
ures 6C, 6D, S6E, and S6F). Thus, CPT1A gene loss in QECs
elevated ROS levels in vivo and rendered them more prone to
oxidative stress upon an inflammatory insult, known to cause
EC dysfunction.
To provide evidence for the dual role of FAO in PECs (prolifer-
ation) versus QECs (redox homeostasis) simultaneously occur-
ring in a single tissue (‘‘mixed model’’), we analyzed freshly
isolated ECs from growing vessels of different organs (heart,
lung, and liver) in control or etomoxir-treated P8 mice upon
5-ethynyl-20-deoxyuridine (EdU) injection to identify EdUpos
PECs and EdUneg QECs by flow cytometry; wemeasured cellular
ROS levels by flow cytometry upon DHE staining. This analysis
showed that, consistent with our previous findings (Schoors
et al., 2015), etomoxir reduced the fraction of PECs, thus
rendering the endothelium more quiescent (Figure S6G). Coinci-
dentally, ROS levels in isolated ECs were increased upon
etomoxir treatment (Figure S6H). Given that the large majority
of ECs were EdUneg QECs and etomoxir further expanded this
population, FAO inhibition elevated oxidative stress in QECs
also in this mixed model containing both PECs and QECs.
FAO Inhibition Causes EC Dysfunction due to Oxidative
Stress
EC dysfunction due to oxidative stress is characterized by a
higher pro-thrombotic state, increased adhesiveness of inflam-
matory leukocytes, and enhanced leakiness (Incalza et al.,
2018; Kevil et al., 2000). We assessed in vitro if FAO inhibitionwith etomoxir and LPS (n = 3).
ter injection of LPS (n = 6).
tomoxir and LPS (n = 3).
t (vehicle) or with etomoxir treatment. White arrowheads denote discontinuous
p between ECs resulting from discontinuous junctions.
hout (vehicle) or with etomoxir treatment (n = 3).
o induce oxidative stress) and with or without the ROS scavenger mitoTEMPO
etomoxir treatment (red lines) and without (solid lines) or with subsequent
nts.
ent with 2.5% DSS in their drinking water for 7 consecutive days (n = 7).
expressed relative to vehicle-treated control group (n = 7).
reatment (n = 7).
tran) in WT and CPT1ADEC mice after DSS treatment (n = 7).
cence model. Since CPT1AKD reduces EC proliferation, precluding these cells
C with etomoxir in order to inhibit FAO in (E), (F), and (H) to (L). Statistics: two-
rroni post hoc test (E, F, and J), mixed models statistics (H and L). Data are
te statistical differences between control and etomoxir, hashtags (#) between
0 mm (C, lower panels), and 100 mm (I). See also Figure S6 and Table S6.
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by etomoxir promoted QEC activation/dysfunction, in baseline
conditions and upon treatment with LPS. First, compared with
control, QECs treated with etomoxir tended to have increased
mRNA levels of the anti-fibrinolytic enzyme plasminogen
activator inhibitor 1 (PAI-1) at baseline, a difference that became
significant upon exposure to LPS (Figure 6E). Second, etomoxir
increased leukocyte adhesion upon activation of QECs with LPS
(Figure 6F). In agreement, infiltration of CD45+ leukocytes into
the lungs of CPT1ADEC mice was increased upon LPS adminis-
tration (Figure 6G). CPT1ADEC mice were more sensitive to
LPS, as they died earlier than WT mice, indicating that reduced
FAO in QECs aggravates the response to LPS (Figure S6I). In
line with this, at 24 hr after LPS injection the serum levels of
pro-inflammatory cytokines (interferon-g [INFg], tumor necrosis
factor a [TNFa], interleukin-5 [IL-5], IL-17, IL-23) were higher in
CPT1ADEC mice (Figure S6J), likely contributing to the shorter
survival. Third, trans-endothelial electrical resistance (TEER)
was lower (reflecting decreased barrier function) in etomoxir-
treated QECs, in both baseline and LPS conditions (Figure 6H).
In agreement, etomoxir-treated QECs contained fewer VE-
cadherin+ continuous stable adherens junctions, in which VE-
cadherin is localized linearly along cell-cell borders (Figures 6I
and 6J). Accordingly, treatment of QECs with trimetazidine
(TMZ), inhibiting long-chain 3-ketoacyl-CoA thiolase (encoded
by HADHB), increased oxidative stress and endothelial
permeability, as demonstrated by reduced TEER levels (Fig-
ure S6K), and increased discontinuous VE-cadherin+ junctions
(Figure S6L).
To assess the role of ROS, we supplemented QECs with
mitoTEMPO, a scavenger of mitochondrial ROS. The induction
of PAI-1 expression in etomoxir and LPS pre-treated QECs
was reduced to control levels after exposure tomitoTEMPO (Fig-
ure 6K). Also, mitoTEMPO treatment of etomoxir-treated QECs
rescued the increased leakiness induced by blocking CPT1A in
QECs (Figure 6L). Together, FAO is a safeguard for QECs to
maintain redox homeostasis, and inhibition of FAO predisposes
QECs to activation and dysfunction when exposed to oxidative
stress.
FAO Inhibition Accelerates DSS-Induced Colitis
To provide additional evidence for a role of FAO in QEC homeo-
stasis, we used a model of inflammatory bowel disease (IBD).
The gut-vascular barrier (GVB) is normally impermeable but
becomes leaky in IBD, thus promoting leukocyte infiltration
and aggravating disease progression (Cibor et al., 2016). Oxida-
tive stress plays a key role in IBD by increasing GVB permeability
(Tian et al., 2017). In addition to leukocytes (the major source of
ROS), ECs also produce ROS in IBD (Oshitani et al., 1993). We
thus hypothesized that the decreased capacity of CPT1ADEC
QECs to scavenge ROS (produced by QECs or other sources)
might aggravate permeability, infiltration of leukocytes, and
overall susceptibility to dextran sodium sulfate (DSS)-induced
colitis.
The disease activity index (DAI) (scoring body weight loss,
stool consistency, and blood in the stool and anal region) was
more severe in CPT1ADEC mice (Figure 6M). Also, in CPT1ADEC
mice, colons shrunk more (Figures 6N and S6M) and displayed
more severe histological signs of colitis, including loss of crypts,
separation of the crypt base from the muscularis mucosa and890 Cell Metabolism 28, 881–894, December 4, 2018colonic wall thickening (Figure S6N), more pronounced infiltra-
tion of CD45+ leukocytes in colons (Figure 6O), and increased
vascular leakiness resulting from a breached QEC barrier (Fig-
ure 6P). At the same time, neovessels formed in the inflamed
colonic mucosa, thus representing a ‘‘mixed model.’’ In line
with previous findings (Schoors et al., 2015), the vessel area
and fraction of proliferating PCNA+ PECs were reduced in
CPT1ADEC mice (Figures S6O and S6P), confirming that FAO
has different biological roles in PECs versus QECs in a single
tissue.
Acetate Supplementation Lowers Oxidative Stress in
QECs of CPT1ADEC Mice
Finally, we explored a possible translational therapeutic poten-
tial. We hypothesized that supplementation of acetate (metabo-
lized to acetyl-CoA, a downstream product of FAO) might lower
ROS levels in QECs, a finding of therapeutic relevance to counter
EC dysfunction. Acetate supplementation of QECs (exposed
to H2O2) prevented the increase in ROS levels upon CPT1A
silencing (Figure 7A). Also, treating CPT1ADEC mice with sodium
acetate prevented the increase in DHE+ ROS levels in QECs
upon LPS treatment (Figures 7B and 7C) and reduced infiltration
of CD45+ leukocytes into the lungs (Figure 7D). Control experi-
ments showed that mitochondrial conversion of acetate to
acetyl-CoA is essential for the rescue by acetate (Figures S7A–
S7G and Table S7).
DISCUSSION
Quiescent ECs Use FAO for Redox Homeostasis
QECs are not hypometabolic, but increase FAO, up to 3- to
4-fold, the largest change of any metabolic pathway flux we
observed in healthy ECs to date (De Bock et al., 2013; Huang
et al., 2017; Schoors et al., 2015; Wong et al., 2017). QECs did
not rely on FAO for ATP production, nucleotide synthesis, or his-
tone acetylation, unlike PECs that utilize FAO to sustain DNA
synthesis (Schoors et al., 2015), or lymphatic ECs that use
FAO for epigenetic regulation of lymphatic gene expression
(Wong et al., 2017).
Instead, QECs utilize FAO for redox homeostasis, partly by re-
generating NADP+ to NADPH likely at the IDH2 andME3 reaction
steps. However, QECs also upregulate the expression of genes
involved in NADP+ production, contributing to improved redox
homeostasis. The importance of CPT1A-driven FAO for redox
homeostasis of QECs in vivo was supported by evidence that
ROS levels were elevated after LPS challenge in QECs of
CPT1ADEC mice. As a consequence of the ROS-mediated induc-
tion of EC barrier dysfunction, leukocyte infiltration into the lung
was increased and survival of CPT1ADEC mice was compro-
mised. A similar outcome was observed when CPT1ADEC mice
were challenged with DSS-induced colitis.
By using FAO for redox homeostasis, QECs differ from other
non-transformed cell types. Indeed, certain immune, glial,
and neural stem cells rely on FAO for energy production (Ghes-
quiere et al., 2014; Stoll et al., 2015), but not for redox balance.
Opposite to the anti-oxidant role of FAO in QECs, M1-like
macrophages even use FAO for the production of bactericidal
mitochondrial ROS (Ghesquiere et al., 2014). Only some cancer





Figure 7. Effect of Acetate Supplementation on Oxidative Stress in Quiescent ECs In Vivo and In Vitro, and Vasculoprotective Gene Expres-
sion in PECs versus QECs
(A) Intracellular ROS levels (CM-H2DCFDA fluorescence) of ctrl and CPT1A
KD QECs, with or without acetate supplementation, upon exposure to H2O2 (50 mM,
2 hr) (n = 5; Dll4 induced quiescence model). AU, arbitrary units.
(B and C) Quantification of O2
. formation (DHE fluorescence normalized for Hoechst fluorescence) of portal vein (B) and aorta (C) open book preparations in WT
or CPT1ADEC mice, at 12 hr after injection with vehicle (PBS) or LPS, with or without acetate treatment (n > 10). Dashed horizontal line, value for untreated WT
control.
(D) Quantification of CD45+ cells in the lungs of WT and CPT1ADEC mice with or without acetate treatment, 12 hr after injection of LPS (n > 10).
(E–H) qRT-PCR analysis of NNT (E) (n = 5), NOS3 (F), PTGS1 (G), and GRX (H) in PECs and contact-inhibited QECs (n = 4).
Statistics: mixed models statistics (A), ANOVA and Bonferroni post hoc test (B–D), two-tailed t test with Welch correction (E–H). Data are mean ± SEM; ns, not
significant, *p < 0.05. See also Figure S7 and Table S7.they mostly use FAO for energy production (Qu et al., 2016),
epithelial-to-mesenchymal transition (Nath and Chan, 2016), or
metastasis (Pascual et al., 2017).
Control of Redox Homeostasis by FAO Counteracts QEC
Dysfunction
Oxidative stress promotes EC activation/dysfunction, leading to
increased vascular thrombogenicity, leakiness, and inflamma-
tion (Incalza et al., 2018; Kevil et al., 2000). Consistent with a
role of FAO in EC redox homeostasis, CPT1A inhibition elevated
ROS levels, leading to decreased anti-fibrinolytic gene expres-
sion, vascular wall leakage in vitro and in vivo, and increased
leukocyte adhesion in vitro and infiltration in vivo. Notably, treat-ment of QECs with a mitochondrial anti-oxidant rescued
vascular leakage, a key feature of EC dysfunction. Blood
vessel-lining QECs are exposed to high levels of oxygen in the
blood and thus to an oxidative stress-prone environment, while
blood vessel-forming PECs invade avascular, hypoxic areas.
We speculate that QECs require a higher level of redox buffering
capacity than PECs.
Molecular Mechanism: Notch at a Crossroad
We show that Notch upregulates CPT1A, IDH2, and ME3
expression by interacting with the DNA-binding protein RBPJk.
As such, Notch signaling constitutes a molecular switch (rheo-
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although other molecular regulators may also contribute. Notch
is known to inhibit DNA synthesis in ECs through induction of the
cell-cycle inhibitor p27KIP1 and suppression of nuclear transloca-
tion of the cell-cycle drivers cyclinD1-cdk4 (Noseda et al., 2004;
Rostama et al., 2015). In agreement, we detected lower expres-
sion of nucleotide synthesis genes in QECs than PECs. This may
explain howNotch signaling redirects the use of FAO from nucle-
otide synthesis in PECs to NADPH regeneration in QECs.
Indeed, by transcriptionally lowering genes involved in nucleo-
tide synthesis, QECs are programmed to no longer use (or use
less) TCA-cycle metabolites for nucleotide synthesis. Thus,
even though FAO sustains the TCA cycle more in QECs than
PECs, QECs are prevented from anabolic synthesis of nucleo-
tides by the cell-cycle inhibitory signaling activity of Notch.
Hence, as a metabolic adaptation accompanying the cellular
shift to quiescence by Notch, QECs no longer/less use FAO for
nucleotide synthesis, even though FAO levels are increased,
but rather to sustain the TCA cycle for NADPH regeneration.
Our findings highlight the plasticity of how a single cell type
(EC) can reprogram the use of the same metabolic pathway
(FAO) for either nucleotide synthesis or redox homeostasis, de-
pending on the cellular status (proliferation versus quiescence).
Our data are not in conflict with a report that Notch signaling in
ECs induces the expression of fatty acid transporters, including
FABP4 (Harjes et al., 2014), and that silencing of FABP4 in PECs
induces oxidative stress and inhibits tumor angiogenesis (Harjes
et al., 2017), since it remains unclear whether FABP4 fuels FAs to
FAO and FABP4 has various FAO-independent activities (Furu-
hashi et al., 2014).
QECs Switch on Additional NADPH-Producing
Vasculoprotective Pathways
Interestingly, QECs also upregulated the expression of other
NADPH-regenerating pathways, such as the oxidative PPP
and nicotine nucleotide transhydrogenase (NNT; converting
NADH [produced by FAO] into NADPH) (Figure 7E), as well as
NADP+-producing pathways. Notably, QECs also upregulated
the expression of enzymes such as eNOS (NOS3), prosta-
glandin G/H synthase 1 (PTGS1), and glutaredoxin (GRX) (Fig-
ures 7F–7H), involved in vasculoprotection against EC dysfunc-
tion induced by oxidative stress (Egan and FitzGerald, 2006;
Heiss et al., 2015). Remarkably, these vasculoprotective en-
zymes use NADPH as cofactor (Davidge, 2001; Ulrich et al.,
2013). Hence, these findings suggest an appealing model
whereby QECs mount a broad vasculoprotective program,
relying on enzymes, several of which require/consume NADPH.
To meet these increased needs of NADPH, QECs reprogram
their metabolism to upregulate NADPH regeneration via
several complementary mechanisms, of which FAO is a major
contributor.
Possible Translational Implications
Consistent with our findings that QECs, exposed to high oxygen
levels and thus prone to oxidative stress, require FAO to secure
redox homeostasis, human QECs expressed higher CPT1A
levels in the highly oxygenated than in the poorly oxygenated
tissues tested (Figures S7H and S7I). Moreover, our findings
that acetate supplementation restored the ROS-scavenging
potential of CPT1A-silenced ECs in the LPS model and normal-892 Cell Metabolism 28, 881–894, December 4, 2018ized the elevated endothelial ROS levels and leukocyte infiltra-
tion in mice lacking endothelial CPT1A suggest that promoting
FAO or stimulating the use of acetate-derived carbons might
be beneficial to counteract EC dysfunction in disease. Given
that EC dysfunction has been postulated to contribute to multi-
ple diseases, in fact more than the dysfunction of other cell
types (Dahlman et al., 2014), identifying such metabolite-based
strategies to counteract/prevent EC dysfunction through
improved anti-oxidant control, might possibly offer therapeutic
opportunities.
Limitations of the Study
Our data highlight that FAO is indispensable for maintaining
redox homeostasis in ECs. Using two different disease models,
we document that loss of CPT1A in ECs induces EC dysfunction
resulting from elevated oxidative stress. Our data also indicate
that acetate treatment is capable of counteracting redox imbal-
ance in conditions of CPT1A suppression. It will be interesting to
explore further whether inadequate FAO levels contribute to dis-
eases characterized by EC dysfunction due to oxidative stress,
and whether acetate supplementation might have therapeutic
potential in counteracting imbalanced oxidative stress, EC
dysfunction, and progression of these diseases.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Animal housing and all experimental procedures were approved by the Institutional Animal Ethics Committee of the KU Leuven
(Belgium). Mice from the EC-specific inducible Cre-driver line Cdh5(PAC)-CreERT2 (Benedito et al., 2009) were crossed with previ-
ously generated Cpt1alox/lox mice (Schoors et al., 2015) to obtain mice with EC-specific deletion of the Cpt1a gene upon tamoxifen
treatment to induce Cre-mediated gene excision (CPT1ADEC mice). These lines were on a 100% C57BL/6 background. Tamoxifen
(Sigma-Aldrich) treatment was done using 8-week-old mice by gavage (0.114 mg/g body weight/day, for 5 consecutive days and
an additional day after a 2-day treatment free interval) one week before the experiment.
Cell Isolation and Culture
Primary Human Umbilical Endothelial Cells
Human umbilical vein endothelial cells (HUVECs) and human umbilical artery endothelial cells (HUAECs) were freshly isolated from
umbilical cords obtained frommultiple donors (with approval from the Ethics Committee Research UZ/KU Leuven and informed con-
sent obtained from all subjects) as previously described (Schoors et al., 2015), regularly tested for mycoplasma. The ECs were main-
tained in M199medium (1 mg/mL D-glucose) (Thermo Fisher Scientific) supplemented with 20% fetal bovine serum (FBS) (Biochrom
BmgH), 2 mM L-glutamine (Thermo Fisher Scientific), Endothelial Cell Growth Supplement (ECGS)/ Heparin (PromoCell), 100 IU/mL
penicillin and 100 mg/mL streptomycin (Thermo Fisher Scientific) or in endothelial cell basal medium (EGM2) (PromoCell) supple-
mented with endothelial cell growth medium supplement pack (PromoCell). In all experiments, HUVECs and HUAECs were always
used as single-donor cultures and were used between passage (p) 1 and 4.
Adult Human Endothelial Cells
As a source of adult human ECs, we used ECs isolated from healthy adjacent tissue from lung or kidney tumor biopsies. Following
surgical resection, adjacent lung or kidney tissue was taken, and transported to the research facility (with approval from the Medical
Ethical Committee KU Leuven/UZ Leuven). Upon arrival, samples were rinsed with PBS (Thermo Fisher Scientific), minced into
smaller pieces of less than 1 mm3, and transferred to 5 mL digestion medium consisting of Dulbecco’s Modified Eagle medium
(DMEM) (4500 mg/L glucose) (Thermo Fisher Scientific), supplemented with 100 U/mL penicillin/streptomycin (Thermo Fisher Scien-
tific), 1 mM sodium pyruvate (Thermo Fisher Scientific), MEM NEAAs (1x) (Thermo Fisher Scientific), 2 mM glutamine (ThermoFisher
Scientific), endothelial cell growth medium supplement pack (PromoCell) and containing 0.2% collagenase I/II (Thermo Fisher Sci-
entific), 250 mg/mL DNase (Sigma-Aldrich) and 0.25 U/mL Dispase (Thermo Fisher Scientific). Samples were incubated for 30 min at
37C, with manual shaking every 5 min. Next, 10 mL cold PBS containing BSA 0.1% (Sigma-Aldrich) were added and the samples
were filtered using a 100 mm strainer (Corning, NY, USA). Following centrifugation at 300 g at RT for 5 min, the supernatant was
decanted and discarded. The cell pellet was resuspended in 6 mL of a mix of M199 (containing 10% FBS and sodium pyruvate,
MEM NEAAs, glutamine and heparin as above) and EGM2 medium (1:1), further supplemented with antibiotic/antimycotic (2x)
(Thermo Fisher Scientific). The single cell suspension was plated out in 3 wells of a 6-well plate pre-coated with 0.1% gelatin
(Sigma-Aldrich). The next day the medium was changed to EGM2 supplemented with antibiotic/antimycotic (Thermo Fisher Scien-
tific) and thereafter refreshed every other day. When reaching confluency and upon detection of EC cell colonies (patches with
cobblestone appearance), the ECs were purified using human anti-CD31 coated magnetic beads according to the manufacturer’s
instructions (MACS Technology, Miltenyi Biotec). The resulting MACS-purified endothelial cells were further cultured in EGM2 me-
dium as single-donor cultures and used for experiments in as early passage as possible (usually up to passage 3-5).
Adult Mouse Endothelial Cells
Mouse ECs were isolated from perfused healthy lungs of adult CPT1ADEC mice and their WT littermates. Briefly, before starting the
perfusion, the mice were anesthetized with Ketamine/Xylazine (500 mL/mouse of Ketamine 0.65%; Xylazine 0.05% diluted inCell Metabolism 28, 881–894.e1–e13, December 4, 2018 e5
physiologic saline solution) and once the withdrawal reflex was absent in pelvic limbs, the perfusion procedure was started. Mice
were perfused with 5 mL of PBS followed by dissection and dissociation of the lung using the Lung Dissociation Kit according to
the manufacturer’s instructions (Miltenyi Biotec), at a perfusion rate of 2 mL/min. Lungs were further dissociated using the
gentleMACS dissociator system (MACS Technology, Miltenyi Biotec). Next, samples were centrifuged, resuspended in 5 mL of
PBS based wash buffer (containing 0.5% BSA; 2 mM EDTA) and applied to a pre-separation 70 mm filter (Corning, NY, USA). The
filtered cells were washed twice with wash buffer and ECs were selected using first CD45 MicroBeads to deplete CD45+ cells
and then labelled with CD31 MicroBeads according to the manufacturer’s instructions (MACS Technology, Miltenyi Biotec).
Positively selected CD31+ cells were stained with viability dye, CD102-APC and CD45-PeCy7 and the fraction of viable, CD102+
and CD45 cells obtained by FACS sorting was directly collected into TRIzol LS reagent (Thermo Fisher Scientific).
Neonatal Mouse (P8) Endothelial Cells
ECswere isolated from perfused lungs, hearts, and livers of P8mice treated with etomoxir (30mg/kg; i.p. injection once a day starting
48 hr before euthanization) or vehicle (0.9% NaCl). To obtain a sufficient number of ECs, organs of three P8 mice of each group were
pooled. For detection of proliferating cells, 5-ethynyl-2’-deoxyuridine (EdU) (Thermo Fisher Scientific) was injected 2 hr before organ
dissection. As described above, mice were anesthetized with Ketamine/Xylazine and the perfusion procedure was started once the
withdrawal reflex was absent in pelvic limbs. Mice were perfused with 1 mL of PBS followed by dissection and dissociated with 5 mL
of a DMEM based digestion buffer containing either 0.2% collagenase II, 0.2% collagenase IV (lungs, hearts) or 0.1% collagenase I,
0.1% collagenase II (livers), Dispase (0.25 U/mL) (livers and hearts) (Thermo Fisher Scientific), 250 mg/mL DNase (Sigma-Aldrich),
2 mM CaCl2, 1% antibiotic/antimycotic, at a perfusion rate of 1 mL/minute. Lungs and hearts were further dissociated using the
gentleMACS dissociator system (MACS Technology, Miltenyi Biotec). Next, samples were centrifuged, resuspended in 5 mL of
PBS based wash buffer (containing 0.5% BSA; 2 mM EDTA) and applied to a pre-separation 70 mm filter (Corning, NY, USA). The
filtered cells were washed twice with wash buffer and ECs were selected using CD45 MicroBeads to deplete CD45+ cells (this
step was only applied to lung and heart tissue) and CD31 MicroBeads according to the manufacturer’s instructions (MACS Technol-
ogy, Miltenyi Biotec). Isolated cells were used immediately to assess ROS levels and cell cycle phase as described in detail below
(See Flow Cytometry Analysis: Analysis Of Endothelial Superoxide Levels and Cell Cycle In Vivo).
METHOD DETAILS
EC Quiescence Models
Contact Inhibition Model of EC Quiescence
ECs (p1 or p2) were seeded in 100% EGM2 at a density of 15,000 cells/cm2. During the progressive induction of EC-quiescence, the
culture medium was gradually changed from 100% EGM2 to M199/EGM2 mix in ratio 1:1 (further referred to as growth medium). To
generate the corresponding proliferative control, contact inhibited cells (day 6 QECs) were trypsinized (using Trypsin-EDTA (0.25%);
Thermo Fisher Scientific) and cultured in growth medium for at least 36 hr to re-initiate proliferation. PECs, used as proliferating
controls for contact-inhibited QECs are always reseeded QECs.
Dll4 Stimulation Model of EC Quiescence
Culture plates were coated overnight at 4C on a plate shaker with 1 mg/mL recombinant human Delta like ligand4 (rhDll4, R&D
Systems) with 0.1% gelatin. The control plates were coated with 0.1% gelatin supplemented with 0.02%BSA (Sigma-Aldrich), which
was used as a carrier for Dll4. Prior to EC seeding, excessive coating solution was removed by aspiration and ECs were seeded at a
density of 30,000 cells/cm2 in growth medium. Experiments were performed 24 hr after seeding. PECs, used as proliferating controls
for Dll4-induced QECs are always ECs grown in parallel on BSA coated plates.
Laminar Shear Stress Model of EC Quiescence
ECs were seeded at a density of 30,000 cells/cm2 in growth medium on SuperFrost Excell object slides (Thermo Scientific Menzel)
overnight and exposed to laminar shear stress (10 dynes/cm2) for 24 hr. The parallel-plate flow chamber system was built in-house
and combined with a peristaltic pump (COLE-PARMER INSTRUMENT 7519-06 Masterflex L/S Cartridge Pump Head, 8-Channel,
4-Roller). HUVECs seeded on SuperFrost object slides overnight were used as static controls.
Knockdown and Overexpression Strategies
Lentiviral Transductions
For overexpression of the Notch intracellular domain (V5-NICD; gift from M. Potente), the cDNA was cloned in the
pRRLsinPPT.CMV.MCS MM W prevector (Wong et al., 2017). To generate shRNA vectors against CPT1A, ACSS1, IDH2, ME3,
ACADvl and HADHB oligonucleotides were cloned into the pLKO-shRNA2 vector (Clontech). A nonsense scrambled shRNA
sequence was used as a negative control. Oligonucleotides are listed in the Key Resources Table. Production of lentiviruses by trans-
fection into 293T cells was performed as described (Wong et al., 2017). For transductions, a multiplicity of infection (MOI) of 5 was
used for all shIDH2 experiments, 10 was used for all shME3, shACADvl and shHADHB experiments, 20 was used in all shCPT1A,
shACSS1 experiments. For transductions with NICD, a MOI of 10 was used. Cells were transduced overnight and re-fed with fresh
medium the next day. Transduced cells were used in functional assays at least 3 to 4 days post-transduction.e6 Cell Metabolism 28, 881–894.e1–e13, December 4, 2018
Transcriptomic Analysis
Microarray Analysis
RNA from PECs and contact-inhibited QECs was extracted, reverse transcribed into cDNA, biotin-UTP labelled using the Illumina
TotalPrep RNA Amplification kit (Thermo Fisher Scientific) and hybridized to the Illumina HumanHT-12 v4 Expression BeadChip
for micro-array analysis using standard protocols (Illumina). Differentially expressed genes and their false discovery rate (FDR) cor-
rected p values were identified by the limma package (Cantelmo et al., 2016). Heatmap analysis was performed using the D3heatmap
package, and significant clusters were calculated via multiscale bootstrap analysis with the Pvclust package (Cantelmo et al., 2016).
The rotation gene set (ROAST) algorithm as implemented in the Iimma package was used to perform self-contained gene set anal-
ysis. Gene expression data were mapped on KEGGmetabolic pathways using Pathview (Cantelmo et al., 2016). Microarray data are
available in GEO (www.ncbi.nlm.nih.gov/geo/) under accession GSE89174.
RNA-sequencing
RNA from freshly isolated murine lung ECs was prepared using TRIzol reagent according to the manufacturer’s instruction. Starting
from 1 mg total RNA, poly-adenylated fragments were isolated, reverse transcribed, and converted into indexed sequencing libraries
using the KAPA stranded mRNA-seq kit (Sopachem, Eke, Belgium). The first 50 bases of these libraries were sequenced on a HiSeq
4000 system (Illumina, San Diego, CA). The raw sequenced reads were mapped to the mouse reference transcriptome and genome
(GRCm38/mm10) using the Bowtie TopHat pipeline. Mapped reads were assigned to Ensembl gene IDs by HTSeq, resulting in on
average 14,814,487 ± 5,948,836 counts per sample. Genes expressed at a level of at least 1 count per million reads in at least three
of eight samples were filtered out with the EdgeR package (Cantelmo et al., 2016), and differentially expressed genes and their false
discovery rate (FDR) corrected p values were identified using Limma (Cantelmo et al., 2016). Heatmap analysis was performed using
the D3heatmap package and significant clusters were calculated via multiscale bootstrap analysis with the Pvclust package (Can-
telmo et al., 2016). The rotation gene set (ROAST) algorithm as implemented in the Limma package (Cantelmo et al., 2016) was used
to perform self-contained gene set analysis. Gene expression data were mapped on KEGG metabolic pathways using Pathview.
RNA-sequencing data are available in GEO (https://www.ncbi.nlm.nih.gov/geo/) under accession E-MTAB-6595.
RNA Isolation and Quantitative RT-PCR
RNA was collected and purified using the PureLink RNA Mini Kit (Thermo Fisher Scientific) and converted to cDNA using the iScript
cDNA synthesis kit (Bio-Rad). For RNA-sequencing validation, RNA from isolated ECs was collected into TRIzol Reagent and ex-
tracted and, then, converted to cDNA using the SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). RNA expression
analysis was performed by Taqman quantitative RT-PCR (Thermo Fisher Scientific) as described using premade primer sets (IDT)
(Schoors et al., 2015). Premade primer set ID numbers are listed in the Key Resources Table. For comparison of gene expression
between conditions, expression (normalized to HPRT endogenous control) is expressed relative to control condition.
Immunoblot Analysis
Protein extraction and immunoblot analysis were performed using amodified Laemmli sample buffer (125mMTris-HCl, pH 6.8 buffer
containing 2% SDS and 10% glycerol) or cell lysis buffer (Cell Signaling Technology) in the presence of protease and phosphatase
inhibitors (Roche). Lysates were separated by SDS-PAGE under reducing conditions, transferred to a nitrocellulose or PVDF mem-
brane, and analyzed by immunoblotting. Primary antibodies used were rabbit anti-CPT1A (Cell Signaling Technology), anti-total
AMPKa (Cell Signaling Technology), rabbit anti-phospho-AMPKa Thr172 (Cell Signaling Technology), anti-PFKFB3 (Cell Signaling
Technology), anti-NICD (Cell Signaling Technology), anti-Histone H2A (Cell Signaling Technology), anti-Acetyl-Histone H2A (Lys5)
(Cell Signaling Technology), anti-Histone H3 (Cell Signaling Technology), anti-Acetyl-Histone H3 (Lys9) (Cell Signaling Technology),
anti-Histone H4 (Cell Signaling Technology), anti-Acetyl-Histone H4 (Lys8) (Cell Signaling Technology), anti-a-tubulin (Sigma) and
anti-acetyllysine (PTM-Biolab). Appropriate secondary antibodies were from Cell Signaling Technology. Signal was detected using
the ECL or Femto system (Thermo Fisher Scientific) according to the manufacturer’s instructions. Densitometric quantifications of
bands were done with Fiji software (https://fiji.sc).
Histone Extraction
ECs were washed with cold PBS, scraped and collected in cold hypotonic lysis buffer (10 mM Tris-HCL (pH 7.5), 1 mM KCl, 1.5 mM
MgCl2, to which was freshly added: 1 mM DTT, 13 protease inhibitors, 10 mM sodium butyrate (Sigma-Aldrich), 0.1% IGEPAL (an
NP-40 substitute; Sigma-Aldrich), 1 mM trichostatin A (TSA; Sigma-Aldrich). The collected samples were incubated for 30 min on a
rotator at 4C to promote hypotonic swelling of cells and lysis by mechanical shearing during rotation. Nuclei were pelleted at
15,000 rpm for 5 min at 4C and immediately resuspended in 0.4 N H2SO4 followed by incubation overnight at 4C. After centrifuga-
tion at 15,000 rpm for 10 min at 4C, histones were precipitated from the supernatant by addition of 20% trichloroacetic acid for 2 hr,
followed by centrifugation at 15,000 rpm for 10 min at 4C. Pellets were washed twice with acetone. Histone proteins were
resuspended in H2O and used for immunoblot analysis.
Flow Cytometry Analysis
In Vivo Analysis of Endothelial Superoxide Levels and Cell Cycle
Wedeveloped a newFACSbasedmethod tomeasure ROS levels and subsequently proliferation of ECs freshly isolated fromdifferent
organs (heart, liver, lung) of P8 neonatal mice, in which blood vessels are still growing and expanding (thus containing PECs) but also
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thereafter for EdU as described below. This avoided that when first stained for EdU, the DHE signal was completely lost due to the
fixation and permeabilization treatment required for the EdU nuclear staining.
Detection of Superoxide Levels in Freshly Isolated Murine ECs. Briefly, freshly isolated Ecs from lungs, hearts, and livers of P8
neonatal mice (as described above) were stained with viability dye, CD45-PeCy7, CD102-APC and DHE (20 mmol/L; Thermo Fisher
Scientific) at 4C for 30min. Next, based on DHE staining we FACS sorted viable, CD45, CD102+ and DHE+ ECs and viable, CD45,
CD102+ and DHE ECs separately into two Eppendorf tubes. The cells were then immediately processed and stained for EdU as
described below.
Cell Cycle Analysis In Freshly IsolatedMurine ECs. Cells in G1were identified as a population positive for EdU incorporation. Briefly,
the DHE+ and DHE FACS sorted ECs from lungs, hearts, and livers of EdU treated P8 mice were fixed with 4% PFA (15 min at RT).
The incorporated EdUwas detected by a ‘click-It reaction’ with Alexa Fluor 488 according to themanufacturer’s instructions (Thermo
Fisher Scientific). Data were recorded by flow cytometry, and analyzed with the FlowJo 8.8.6 software (https://www.flowjo.com).
Cell Cycle Analysis In Vitro
Cells in G0 were identified as a 2N DNA population lacking EdU incorporation. Briefly, cells were labeled with 10 mM EdU over 24 hr,
collected by trypsinization and fixed (4% PFA). The incorporated EdU was detected by a ‘click-It reaction’ with Alexa Fluor 647
according to the manufacturer’s instructions (Thermo Fisher Scientific). Data were recorded by flow cytometry, and resultant data
were analyzed with the FlowJo 8.8.6 software (https://www.flowjo.com).
Metabolic Assays
Fatty Acid Oxidation
ECs were incubated in fully supplemented growth medium, supplemented with 100 mM unlabeled palmitate and 50 mM carnitine
(Sigma-Aldrich). Cells were incubated for 6 hr in growth medium containing 2 mCi/mL [9,10-3H]palmitatic acid (Schoors et al.,
2015; Wong et al., 2017) (Perkin Elmer). Thereafter, supernatant was transferred into glass vials sealed with rubber stoppers.
3H2O was captured in hanging wells containing aWhatman paper soaked with H2O over a period of 48 hr at 37
C to reach saturation
(Schoors et al., 2015). Radioactivity was determined by liquid scintillation counting.
Glycolysis
Glycolysis was measured analogously to fatty acid oxidation (see above) using 80 mCi/mmol [5-3H]D-glucose (Perkin Elmer)
(Schoors et al., 2015).
Fatty Acid Synthesis
ECs were incubated in growth medium supplemented with [U-14C]acetate (Perkin Elmer) for 24 hr following snap freezing and
methanol-water-chloroform extraction. Phase separation was achieved by centrifugation at 4C and the methanol-water phase
containing polar metabolites was used as negative control. Chloroform phase containing fatty acids was added to scintillation liquid
and counts were normalized to protein concentrations determined of the dried protein interphase.
14C-glucose Oxidation
Cells were incubated for 6 hr in growth medium containing 100 mCi/mmol [6-14C]D-glucose (Perkin Elmer). Thereafter, 250 mL of 2 M
perchloric acid was added to eachwell to stop cellularmetabolism andwells were immediately coveredwith a 1x hyamine hydroxide-
saturatedWhatman paper. Overnight absorption of 14CO2 released during oxidation of glucose into the paper was performed at room
temperature, and radioactivity in the paper was determined by liquid scintillation counting.
14C-glutamine Oxidation
14C-glutamine Oxidation was performed similarly as glucose oxidation, except that 0.5 mCi/mL [U-14C]glutamine (Perkin Elmer) as
tracer was used.
Oxidative Pentose Phosphate Pathway
The oxidative pentose phosphate pathway (oxPPP) flux was measured as 14CO2 formation using [6-
14C]D-glucose (Hartmann
Analytic) (14CO2 formation only in the TCA cycle) and [1-
14C]D-glucose (Hartmann Analytic) (14CO2 formation in both the TCA cycle
and the oxPPP). Cells were incubated in parallel in medium containing [6-14C]D-glucose (1 mCi/mmol) or medium containing [1-14C]
D-glucose (1 mCi/mmol). Released 14CO2 was captured in a similar manner as described above for the glucose or glutamine
oxidation. The oxPPP flux was then calculated by subtracting the [6-14C]D-glucose flux from the [1-14C]D-glucose flux and was
normalized to the glycolytic flux to correct for total cellular glucose usage.
Palmitate Mediated DNA, RNA and Protein Synthesis
Palmitate mediated DNA, RNA and protein synthesis was measured by the incorporation of 14C into DNA, RNA or protein using
100 mCi/mmol [U-14C]palmitic acid (Perkin Elmer) and was corrected for the total amount of DNA/RNA per sample. Total DNA/
RNA was extracted using TRIzol Reagent as an alternative extraction method for DNA and RNA.
ATP Measurement
Analysis of total ATP levels was performed using a commercially available kit (ATPlite, PerkinElmer).
Oxygen Consumption
Cells were seeded at 30,000 cells per well on Seahorse XF24 tissue culture plates (Seahorse Bioscience Europe). The oxygen con-
sumption was measured over a period of 2 min. At any condition, 5 consecutive measurements of OCR are done. After OCR mea-
surement at baseline conditions, oligomycin, a blocker of ATP synthase is injected at 12 mM (final concentration in the cell 1.2 mM) to
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Detection of Glutathione Species, NADPH and dNTPs
Metabolites from ECs grown on a 6-well plate were extracted in 300 mL of a 50:30:20 (methanol: acetonitrile: 20 mM Tris, pH 9.3)
extraction buffer. Extraction samples were then centrifuged for 5 min at 15,000 x G and the supernatant was transferred to
LC-MS vials. Targeted measurements of GSSG, GSH, NADP+, NADPH, dATP, dTTP and dCTP were performed using a Dionex
UltiMate 3000 LC System (Thermo Scientific) coupled to a Q Exactive Orbitrap mass spectrometer (Thermo Scientific) operated
in negative mode. Practically, 35 mL of sample was injected on a SeQuant ZIC/ pHILIC Polymeric column (Merck Millipore). The
gradient started with 20% of solvent B (10 mM NH4-acetate in MQH2O, pH 9.3) and 80% solvent A (LC-MS grade acetonitrile)
and remained at 20%B until 2 min post injection. Next, a linear gradient to 80%Bwas carried out until 29 min. At 38 min the gradient
returned to 40% B followed by a decrease to 20% B at 42 min. The chromatography was stopped at 58 min. The flow was kept con-
stant at 100 mL per min at the column was placed at 25C throughout the analysis. The MSwas operated both in targeted MS2mode
using a spray voltage of 3.5 kV, capillary temperature of 320C, sheath gas at 10.0, auxiliary gas at 5.0. For the targeted MS2 mode,
AGCwas set at 2e5, maximum IT at 100ms, a resolution of 17.500 and an isolation window of 1.2m/z. Data collection was performed
using Xcalibur software (Thermo Fisher Scientific).
Glucose Consumption
Cells were incubated for 24 hr in growth medium. To 20 mL of medium 80 mL of 100%methanol was added and kept for 3 hr at80C
in order to precipitate proteins. Following a centrifugation at 20,000 x g for 10 min, the supernatant was dried using a vacuum centri-
fuge. To the dried fraction, 50 mL of hydroxylamine hydrochloride solution (20 mg/mL in pyridine) was added. The samples were
heated at 90C for 60 min, followed by the addition of 100 mL of propionic anhydride. After 30 min incubation at 60C, the samples
were again evaporated to dryness and dissolved in 100 mL of ethyl acetate and transferred into GC vials for GC-MS analysis. The
injection volume was 1 mL and samples were injected using a 1:20 split ratio. GC oven temperature was held at 80C for 1 min,
increased to 280C at 20C per min, and held for 3 min. The mass spectrometer operated in SIMmode and glucose was determined
from the fragment at m/z 370 (C17H24O8N1), which contains carbon atoms C1–C5 of glucose. Data collection was performed using
Xcalibur software.
Energy Balance Assessment
Samples were collected in 300 mL cold (chilled on dry ice) 50:30:20 (methanol: acetonitrile: 20 mM Tris, pH 9.3) extraction buffer and
100 mL of themixture was injected onto an Agilent 1260 HPLC equipped with a C18-Symmetry column (150 x 4.6mm; 5 mm) (Waters),
thermostatted at 22.5C. Flow rate was kept constant at 1 mL/min. A linear gradient using solvent A (50 mM NaH2PO4, 4 mM tetra-
butylammonium, adjusted to pH 5.0 using H2SO4) and solvent B (50 mM NaH2PO4, 4 mM tetrabutylammonium, 30% CH3CN,
adjusted to pH 5.0 using H2SO4) was accomplished as follows: 95% A for 2 min, from 2 to 25 min linear increase to 100% B,
from 25 to 27 min isocratic at 100% B, from 27 to 29 min linear gradient to 95% A and finally from 29 to 35 min at 95% A. Detection






13C Tracer Experiments and Metabolite Levels
For 13C-carbon incorporation from palmitate in metabolites, cells were incubated for 48 hr with labeled substrates. For ECs, [U-13C]
palmitate, [U-13C]glucose, [U-13C]glutamine, [U-13C]acetate labeling was done in the setting of 100% labeling, whereby all cold me-
tabolites in growth medium were replaced by 100 mM [U-13C]palmitate, 5.5 mM [U-13C]glucose, 2 mM [U-13C]glutamine (Cambridge
isotope laboratories) or 500 mM [U-13C]acetate (Sigma-Aldrich) respectively. For palmitate labelling charcoal stripped serum (which
does not contain any fatty acids) was used in growth medium (Sigma-Aldrich). Metabolites for the subsequent mass spectrometry
analysis were prepared by quenching the cells in liquid nitrogen followed by a cold two-phase methanol-water-chloroform extraction
(Schoors et al., 2015). Phase separation was achieved by centrifugation at 4C and the methanol-water phase containing polar me-
tabolites was separated and dried using a vacuum concentrator. The dried metabolite samples were stored at80C (Schoors et al.,
2015). Polar metabolites were derivatized for 90 min at 37Cwith 7.5 mL of 20mg/mLmethoxyamine in pyridine and subsequently for
60 min at 60C with 15 mL of N-(tert-butyldimethylsilyl)-N-methyl-trifluoroacetamide, with 1% tert-butyldimethyl-chlorosilane
(Schoors et al., 2015). Isotopomer distributions andmetabolite levels weremeasured with a 7890AGC system (Agilent Technologies)
combined with a 5975C Inert MS system (Agilent Technologies). One microliter of sample was injected onto a DB35MS column in
splitless mode using an inlet temperature of 270C (Schoors et al., 2015). The carrier gas was helium with a flow rate of 1 mL per
min. Upon injection, the GC oven was held at 100C for 3 min and then ramped to 300C with a gradient of 2.5C per min. The
MS system was operated under electron impact ionization at 70 eV and a mass range of 100–650 amu was scanned. Isotopomer
distributions were extracted from the raw ion chromatograms using a custom Matlab M-file, which applies consistent integration
bounds and baseline correction to each ion. In addition, we corrected for naturally occurring isotopes using themethod of Fernandez
et al. (Fernandez et al., 1996). For relative metabolite levels, the total ion count was normalized to the internal standards norvaline and
glutarate and to the protein content. To correct for enrichment dilution, we used previously reported methods, i.e. we divided theCell Metabolism 28, 881–894.e1–e13, December 4, 2018 e9
fractional contribution of a labeledmetabolite of interest by the fractional contribution of its precursor. The total contribution of carbon
was calculated using the following equation:










Herewith, ‘‘n’’ is the number of C atoms in the metabolite, ‘‘i’’ represents the different mass isotopomers and ‘‘m’’ refers to the
abundance of a certain mass. Glycolytic carbon contribution was calculated based on [U-13C]glucose labeling and label dilution
in pyruvate . For total metabolite levels, arbitrary units of the metabolite of interest were normalized to the protein content.
PC-dependent anaplerosis was estimated from the difference of m+3 malate and m+3 succinate using [U-13C]glucose, as
described previously (Christen et al., 2016). Briefly, malate m+3 from [U-13C]glucose is generated by PC flux, but can also arise
from an oxidative TCA cycle flux. Succinate m+3 from [U-13C]glucose can arise from an oxidative TCA cycle flux, but not from PC
flux (given that reverse succinate dehydrogenase flux is marginal or not present). Thus, under the prerequisite that pyruvate enrich-
ment from [U-13C]glucose is similar, comparing malate m+3 and succinate m+3 allows to conclude about relative changes of
PC-dependent anaplerosis.
In Vitro Functional Assays
Proliferation
EC Proliferation was quantified by incubating cells for 2 hr with 1 mCi/mL [6-3H]thymidine (Perkin Elmer). Thereafter, cells were fixed
with 100% ethanol for 15 min at 4C, precipitated with 10% TCA and lysed with 0.1 N NaOH. The amount of [6-3H]-thymidine incor-
porated into DNA was measured by scintillation counting.
LDH Viability Assay
Cell survival was assessed by lactate dehydrogenase (LDH) release into the media using the LDH assay kit (Roche) as indicated in
manufacturer’s specifications, whereby low LDH release signifies low cell death and high survival. 1.2 mMoligomycin (Sigma-Aldrich)
was used to verify whether pharmacological targeting of ATP can affect viability of ECs upon induction of quiescence and or
CPT1AKD.
Trans-endothelial Electrical Resistance
25,000 ECs were seeded in growth medium on 6.5 mm 0.1% gelatin-coated polyester transwells, 0.4 mm pore size (Costar ref. 3470,
Sigma-Aldrich). The trans-endothelial electrical resistance (TEER) was measured using the Endohm-6 electrode (World Precisions
Instruments) connected to an EVOM2 voltohmmeter (World Precisions Instruments). Gelatin-coated wells without cells were used
to measure the intrinsic electrical resistance of the inserts and these values were then subtracted to the values measured in the pres-
ence of cells. Measurements were performed every day, taking at least 2 measurements per treatment. Overnight incubation with
etomoxir (100 mM) and trimetazidine (TMZ) (250 mM; Sigma-Aldrich) was used to assess the effect of pharmacological FAO inhibition,
LPS (1 mg/mL) (Escherichia coli, 0111:B4, Sigma-Aldrich) was used to assess the effect of the stressors, hydroxycitrate (HCA) (1mM;
Sigma-Aldrich) was used to assess the inhibition of ATP-dependent citrate lyase. The mitochondrial ROS scavenger mitoTEMPO
(Sigma-Aldrich) was used with a concentration of 5 mM.
Leukocyte Adhesion Assay
Whole blood from healthy human volunteers was collected (with approval from theMedical Ethical Committee KU Leuven/UZ Leuven
and informed consent obtained from all subjects) and anticoagulated with K2EDTA (1.8 mg/mL, using plastic whole blood spray-
coated K2EDTA tubes, Bection Dickinson). Peripheral blood mononuclear cell (PBMC) were isolated by gradient centrifugation
over Ficoll-paque plus (GE healthcare). PBMCs were labelled with Calcein (cell-permeant dye, Thermo Fisher Scientific). HUVECS
(plated 7 days before (7.5 x 104 cells/well, 12-wells plate), were washed with PBS and incubated either with vehicle (sterile PBS),
etomoxir (100 mM) or LPS (1 mg/mL) overnight (37C, 5% CO2). After this period, medium was removed and ECs were washed
with PBS. The mononuclear cells were added (5 x 105/well) and incubated for 60 min (37C, 5% CO2). Non-adherent cells were
removed by washing 5 times with PBS and cells where fixed using 4% PFA. Five fields per well, randomly chosen, were analyzed,
and the number of adherent leukocytes per field was determined using a Leica DMI6000B microscope (magnification 20X).
Analysis of ROS Species
Intracellular ROS Analysis
Intracellular ROS levels were measured using 5-(and-6)-chloromethyl-20,70-dichlorodihydrofluorescein diacetate, acetyl ester (CM-
H2DCFDA) according to the manufacturer’s instructions (Thermo Fisher Scientific). CM-H2DCFDA is metabolized by intracellular
esterases to a non-fluorescent molecule, which is oxidized by H2O2 to the fluorescence product CM-DCF. The intracellular ROS
levels were determined by pre-incubation of the ECs for 30 min with 10 mM CM-H2DCFDA and H2O2 scavenging capacity was
determined after a subsequent incubation for 0-2 hr with 50 mM H2O2 (Merck, Milipore) in serum free M199. The mitochondrial
ROS scavengermitoTEMPO (Sigma-Aldrich) was usedwith a concentration of 5 mM. The fluorescent intensity wasmeasured accord-
ing to the manufacturer’s instructions.
Mitochondrial ROS Analysis via MitoSOX
Intracellular accumulation of superoxide was estimated using MitoSOX Red (Thermo Fisher Scientific), which is selectively targeted
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loadedwithMitoSOX at 2.5 mM for 30min, collected by trypsinization andwashedwith PBS supplementedwith 2%FBS. Using a flow
cytometer, MitoSOX Red was excited at 488 nm and fluorescence emission at 575 nm was measured. Fluorescence intensity was
used as measurement of mitochondrial superoxide production and the data were analyzed with the FlowJo 8.8.6 software.
Total Levels of H2O2
Total levels of H2O2 were measured by using the Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Thermo Fisher Scientific),
according to the manufacturer’s instructions.
Mitochondrial Levels of H2O2
Measurements of the mitochondrial levels of H2O2 were performed using the HyPER-dMito probe (Evrogen) as previously described
(Belousov et al., 2006). Briefly, ECs were transduced overnight with HyPER-dMito (cloned in the pRRLsinPPT.CMV.MCS MM W
prevector) and re-fed with fresh medium the next day. Transduced cells were used for confocal imaging using a Zeiss LSM 780
confocal microscope (oil objective: x40) (Carl Zeiss) and were treated with or without 50 mM H2O2 for 10 min. Cells were placed in
the microscope stage incubator and HyPER-dMito fluorescence was activated by 488 nm or 405 nm laser. Band pass 530/40
emission filter was used in both cases. For each condition 10 independent images were taken. To assess mitochondrial levels of
H2O2, the ratio of fluorescence intensity upon excitation at 488nm over fluorescence intensity upon excitation at 405 nm (ratio
488/405 nm) was calculated.
OH Detection by Electron Paramagnetic Resonance (EPR) Spectroscopy
Quiescent (QEC) or proliferating cells (PEC) were washed twice with PBS and incubated for 3-5 min with trypsin/EDTA at 37C.
Harvested cells were centrifuged for 5 min at 1,200 rpm, washed with DPBS, and resuspended in PBS at a concentration of
2x106 cells/mL. Spin trapping reagents 5-diisopropoxyphosphoryl-5-methyl-1-pyrroline N-oxide (DIPPMO, final concentration
50 mM) (Enzo Life Science) and diethylenetriaminepentaacetic acid (DTPA, final concentration 1 mM) (Sigma-Aldrich) were added
and the solution was transferred to a flat quartz cell for the EPRmeasurements. This ensured reproducible measurement as thewhole
resonator was filled with the same volume of material. For measurement on lysates, cells were lysed by sonication (20 s, Labsonic U,
B. Braun). For control experiments with superoxide dismutase-polyethylene glycol (SOD-PEG, final concentration 200 U/mL) (Sigma-
Aldrich) or catalase-peg (CAT-PEG, final concentration 100 U/mL) (Sigma-Aldrich), cells were preincubated for 30min (37C) with the
appropriate enzyme before adding the spin trap reagents. EPR measurements were performed using a Bruker EMX-Plus spectrom-
eter (Bruker, Rheinstetten, Germany), operating in X-band (9.85 GHz) and equipped with a SHQ high- sensitivity resonator. Settings
used were as follows: microwave power: 20 mW; modulation frequency: 100 kHz; modulation amplitude: 0.1 mT (lysate) or 0.2 mT
(cells); receiver gain: 60 dB; time constant: 10.24 ms; conversion time, 50.04 ms; data points, 1024; sweep width, 20 mT; number of
scan: 15. Computer simulations were performed using Winsim from the Public Electron Paramagnetic Resonance Software Tools
library of the NIH (USA).
Immunochemistry and Morphometry
Quantification of VE-cadherin Junctions
Cells were fixed with 4%PFA for 10min at room temperature and subjected to immunofluorescence staining for adherence junctions
using anti-VE-cadherin (Thermo Fisher Scientific) and Alexa-488 Fluor conjugated phalloidin (Thermo Fisher Scientific). Alexa-568
or -647 conjugated secondary antibodies were used (Thermo Fisher Scientific). Imaging was performed using a Zeiss LSM 780
confocal microscope (oil objectives: x40 NA 1.3, x63 NA 1.4, x100 NA 1.46) (Carl Zeiss). Junctional length was calculated by
measuring the length of all segments of continuous and discontinuous junctions on confluent ECs stained for VE-cadherin as
described (Cantelmo et al., 2016). The sum of all segments was considered the total junctional length (100%), and the sum of all
discontinuous segments was calculated as the percentage of total junctional length. A minimum of 5 fields was quantified (z30 cells
per field) per experiment.
b-galactosidase Senescence Staining
Stainingwas performed as previously described (Debacq-Chainiaux et al., 2009). Briefly, The EC cultures were fixed for 5min at room
temperature with fixation solution (2% formaldehyde (vol/vol) and 0.2% glutaraldehyde (vol/vol) in PBS) followed by overnight
incubation with the staining solution (40 mM citric acid/Na phosphate buffer, 5 mM K4[Fe(CN)6], 5 mM K3[Fe(CN)6], 150 mM sodium
chloride, 2 mMmagnesium chloride) and 1 mg/mL X-gal (Thermo Fisher Scientific) in distilled H2O. Cells were rinsed twice with PBS
and once with 100%methanol. The stained cell culture plates were protected from the light and air-dried. The b-galactosidase stain-
ing was imaged using phase-contrast microscopy.
PCR Chromatin Immunoprecipitation
Cultured cells, treated or not with the Notch inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT;
10 mM) (Sigma-Aldrich) overnight, were fixed with 1% formaldehyde (16% formaldehyde (w/v), Methanol-free, Thermo Fisher Scien-
tific) for 8 min. Glycine (125 mM) was added for 5 min. Cells were washed twice with ice-cold PBS 0.5% Triton-X100, scraped and
collected by centrifugation (1,000 3 g for 5 min at 4C). The pellet was resuspended in 1,400 mL of modified RIPA buffer (50 mM
Tris-HCl pH 8, 150 mM NaCl, 2 mM EDTA pH 8, 1% Triton-X100, 0.5% Sodium deoxycholate, 1% SDS, 1% protease inhibitors).
The lysate was sonicated for 4 min by using a 250 Digital Sonifier (Branson) with 0.7 s ’On’ and 1.3 s ’Off’ pulses at 40% power ampli-
tude, yielding a DNA fragments between 100 and 1,000 bp. The lysate was centrifuged for 10 min at 16,000 3 g (4C), and super-
natant transferred to a new eppendorf tube. 50 mL of sheared chromatin was set apart as ‘‘input’’, and 5 mg of either rat anti-Notch1
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were incubated overnight at 4C on a rotator. 20 mL Pierce Protein A/GMagnetic Beads (Thermo Fisher Scientific) were added to the
samples and incubated at 4C for at least 5 hr. A/G Magnetic Beads were collected and washed 5 times with washing buffer (50 mM
Tris-HCl, 200mMLiCl, 2 mMEDTA, pH 8, 1%Triton, 0.5%Sodium deoxycholate, 0.1%SDS, 1%protease inhibitors), and twice with
TE buffer. The A/G magnetic beads were resuspended in 50 mL of TE buffer, and 1.5 mL of RNase A (Thermo Fisher Scientific)
was added to the A/G beads samples and to the input, followed by incubation for 30 min at 37C. After addition of 1.5 mL of
proteinase K (Thermo Fisher Scientific) and overnight incubation at 65C in a thermoshaker (800 rpm), the DNA was purified using
1.8 3 volume of Agencourt AMPure XP (Beckman Coulter) according to the manufacturer’s specifications, and eluted in 20 mL of
TE buffer (Thermo Fisher Scientific). The input, control IgG and immunoprecipitated DNA fractions were then subjected to quantita-
tive PCR using SYBR Green (PowerUp SYBR Green, Thermo Fisher Scientific). Primer sequences are listed in the Key Resources
Table. Raw Ct values were analyzed and results were presented as % of input.
Luciferase Reporter Assay
Sequences verified by PCRwere cloned into the pGL3 basic luciferase plasmid (Promega) lacking promoter and enhancer elements.
HUVECs were transduced with control lentiviruses or NICDOE lentiviruses. Four days after viral transduction, cells were trypsinized
and transfected with empty pGL3 plasmids or plasmids containing sequences of the CPT1A promoter, as identified by chromatin
immunoprecipitation (ChIP)-qPCR, using Nucleofector transfection reagent (Lonza), as per manufacturer’s specifications. Cells
were co-transfected with the respective luciferase reporters and also the Renilla plasmid, as a control, and allowed to grow for
72 hr before being collected with PBS, centrifuged, then lysed. Luciferase activity was measured by Dual Luciferase Reporter Kit
(Promega) according to the manufacturer’s specifications.
Mouse Studies
In Situ Detection of ECs Superoxide Levels
Aortas and portal veins were harvested from the animals at 4 or 12 hr after LPS injection (10 mg/kg, i.p.) and treated i.p. with 400 mL
vehicle or 0.5 M sodium acetate (Sigma-Aldrich) solution daily, were opened longitudinally for en-face dehydroethidium (DHE;
Thermo Fisher Scientific) staining. DHE (20 mmol/L) was topically applied to the samples and incubated in a light-protected humidified
chamber at 37C for 30 min followed by Hoechst33342 (1 mg/mL; Thermo Fisher Scientific) staining for 15 min and finally Alexa-647
conjugated isolectin B4 (Thermo Fisher Scientific) for 1 hr. Imaging was performed immediately using a Zeiss LSM 780 confocal
microscope (oil objective: x40 NA 1.3) (Carl Zeiss). The endothelium was identified by an isolectin B4 positive signal. For all images
in a single experiment, the samples were all stained at the same time, and acquisition settings were kept constant for all image
acquisitions. Quantification of DHE fluorescence intensity was performed using Fiji software. Average intensity images were
generated and ECs nuclei were selected using the particle-analyzer tool. Per sample, 5 images were analyzed and corrected total
cell fluorescence was calculated for DHE.
Determination of Cytokine Concentrations
Levels of cytokines weremeasured in blood serumof LPS treatedCPT1ADECmice and theirWT littermates usingMACSPlex Cytokine
Kit according to the manufacturer’s instructions (mouse, Miltenyi Biotec).
Leukocyte Infiltration into the Lungs
Lungs were dissected and fixed in 4% PFA overnight at 4C, dehydrated, embedded in paraffin and sectioned. Immunostaining of
leukocytes was done with rat anti-Mouse CD45 antibody (BD Pharmingen). The sections were then incubated with an appropriate
secondary antibody (Jackson Immuno Research) and TSA Cy3 amplification (Perkin Elmer). Nuclei were counterstained with
Hoechst33342. Imaging was performed using a Leica DMI6000B inverted microscope (Leica Microsystems). Morphometric analysis
of the CD45+ area in % of lung area was done using Leica MM AF powered by MetaMorph analysis software.
DSS-induced Acute Colitis Model
CPT1ADEC and WT mice were exposed to vehicle or 2.5% dextrane sulfate sodium (DSS) (36,000-50,000 M.Wt., MP Biomedicals) in
their drinking water for 7 consecutive days. The severity of colitis was evaluated by assessing the disease activity index (DAI) (which
scores body weight loss, stool consistency, and blood in the stool and anal region) of CPT1ADEC andWTmice under DSS treatment.
On day 7, mice were injected via the tail vein with dextran-rhodamine (70,000 kDA, Thermo Fisher Scientific). Ten min after injection,
mice were perfused and fixed (using 1% PFA perfusion) and the colon was harvested and processed for immunohistochemistry. Co-
lon sections were stained with H&E for morphological analyses, with anti-CD105 (R&D Systems) to identify blood vessels, anti-CD45
antibodies to analyze immune cell infiltration and PCNA to identify proliferating cells. The sectionswere then incubatedwith an appro-
priate secondary antibody (Jackson Immuno Research) and TSA Fluorescein or TSA Cy5 amplification (Perkin Elmer) when needed.
Nuclei were counterstained with Hoechst33342 (Thermo Fisher Scientific). Imaging was performed using a Leica DMI6000B inverted
microscope (Leica Microsystems). The leakiness of the vessels was measured by quantifying the extravascular dextran-rhodamine
positive area. Morphometric analysis of the CD45+ area in % of colon area was done using Leica MM AF powered by MetaMorph
analysis software. Quantification of the vessel area in the colonic mucosa was done using Fiji software. EC proliferation was
measured as the number of PCNA+ CD105+ ECs and expressed as a percentage of the total number of CD105+ ECs per imaged filed
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Human Tissue Analysis
In Situ Detection of CPT1A in the Vasculature
Human lung and kidney sections, obtained from Pathology Department from University of Leuven (KU Leuven), were used for immu-
nostaining with anti-CD31 (Dako) and anti-CPT1A (Proteintech) primary antibodies. Appropriate fluorescently conjugated secondary
antibodies (Jackson Immuno Research) were used, followed by TSA Cy5 amplification (Perkin Elmer) when needed. Imaging was
performed immediately using a Zeiss LSM 780 confocal microscope (oil objective: x40) (Carl Zeiss).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data represent mean ± SEMof at least three independent experiments. Statistical significancewas calculated by standard two-tailed
t test with Welch’s correction, ANOVA (for multiple comparisons within one dataset), one sample t test (for comparisons to point-
normalized data) and by log-rank test (for comparisons of survival distributions of two groups) using Prism v6.0f. When inter-exper-
imental variability was large between experiments with ECs isolated from individual umbilical cord donors, mixed model statistics
(R version 3.2.4 using Kenward-Roger approximation) was used with experiment (i.e. donor) as random factor to correct for con-
founding variation between individual EC isolations. Self-contained gene set analysis was performed via rotation gene set analysis
(R, Iimma package). P < 0.05 was considered statistically significant.
DATA AND SOFTWARE AVAILABILITY
Data Resources
Themicroarray data have been deposited in theGEOdatabase under accession numberGEO:GSE89174. The RNA sequencing data
have been deposited in the Array Express under accession number Array Express: E-MTAB-6595.
Software
All software is freely or commercially available and is listed in the STAR Methods description and Key Resources Table.Cell Metabolism 28, 881–894.e1–e13, December 4, 2018 e13
